Talphera (TLPH) Income towards Parent Company (2010 - 2025)

Talphera (TLPH) posted quarterly Income towards Parent Company of $73000.0 for Q1 2025, up 708.33% quarter-over-quarter from -$12000.0 in Q4 2023.

Talphera (TLPH) Income towards Parent Company (2010 - 2025) Analysis & Trends

Talphera's Income towards Parent Company history runs 15 years deep, the most recent figure standing at $73000.0 for Q1 2025.

In Q1 2025, Income towards Parent Company changed N/A year-over-year to $73000.0; the TTM figure through Dec 2025 stood at $73000.0 (changed N/A YoY), while the FY2025 annual figure was $73000.0, changed N/A from the prior year.
Income towards Parent Company for Q1 2025 stood at $73000.0, up from -$12000.0 in the prior quarter.
The five-year high for Income towards Parent Company was $8.2 million in Q1 2023, with the low at -$9.9 million in Q2 2021.
The 4-year median for Income towards Parent Company is -$1.5 million (2022), against an average of -$2.4 million.
The sharpest annual moves came in 2022 and 2023: Income towards Parent Company tumbled 185.61% in 2022, then surged 302.41% in 2023.
Talphera's Income towards Parent Company stood at -$542000.0 in 2021, then sank by 185.61% to -$1.5 million in 2022, then soared by 99.22% to -$12000.0 in 2023, then soared by 708.33% to $73000.0 in 2025.
Business Quant data shows TLPH's Income towards Parent Company at $73000.0 in Q1 2025, -$12000.0 in Q4 2023, and $61000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.81 Bn	42.84 Bn	-
2	Teva Pharmaceutical Industries	43.29 Bn	39.63 Bn	2.15 Bn
3	Zoetis	31.59 Bn	29.91 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.67 Bn	22.88 Bn	5.10 Bn
5	United Therapeutics	22.24 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.79 Bn	17.91 Bn	1.46 Bn
7	Neurocrine Biosciences	15.71 Bn	15.32 Bn	935.80 Mn
8	Elanco Animal Health	12.09 Bn	11.56 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-
10	Talphera	89.50 Mn	89.50 Mn	-

Download Data